Paper Details

  1. Home
  2. Paper Details

The results of the comparative study of nadolol, propranolol, prazosin and hydrochlorothiazide in patients with arterial hypertension in a 12-month stepped-plan treatment (cooperative research). The Working Group of the Cooperative Program to Study New Preparations in the Prevention of Arterial Hypertension. II. The results of combined therapy. Side effects. The reasons for dropouts. Conclusion.

Author: FilatovaN P, MetelitsaV I

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Nadolol (N), a beta-blocker, was found to be effective and safe for long-term treatment of arterial hypertension. In a study involving 419 men, N was as effective as propranolol (PP), prazosin (PS), and a diuretic (D). N had a longer duration of action than PP and was associated with fewer side effects compared to other drugs.
Paper Details　
Original Abstract of the Article :
The efficacy and safety of nadolol (N), propranolol (PP), prazosin (PS) and a diuretic (D) were studied and compared with the aid of a total systems approach in a cooperative open study with participation of 10 centers of the USSR. As many as 419 men suffering from arterial hypertension (diastolic A...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1792613

データ提供：米国国立医学図書館（NLM）

A New Era of Testicular Cancer Treatment

Testicular cancer is a disease that once posed a significant threat to men's health. This research chronicles the groundbreaking advancements in testicular cancer treatment, showcasing the transformative impact of cisplatin-based chemotherapy.

Cisplatin: A Game-Changer in Cancer Treatment

The introduction of cisplatin combination chemotherapy revolutionized the treatment landscape for testicular cancer. The study demonstrates the remarkable effectiveness of cisplatin-based regimens, significantly increasing the cure rate compared to older therapies. The researchers meticulously document the evolution of treatment strategies, highlighting the key role of cisplatin in achieving high rates of complete remission and long-term disease-free survival.

Conquering Cancer: A Collaborative Effort

This research stands as a testament to the collaborative efforts of researchers, clinicians, and patients in advancing cancer treatment. The success story of testicular cancer serves as an inspiration, demonstrating the power of scientific innovation and the unwavering pursuit of improved patient outcomes. This study underscores the vital role of research in transforming the lives of countless individuals impacted by cancer.

Dr.Camel's Conclusion

Testicular cancer treatment has come a long way, from a once formidable foe to a now highly curable disease. This study highlights the pivotal role of cisplatin-based chemotherapy, a beacon of hope that has significantly improved patient outcomes. Just as a camel navigates the desert with resilience and determination, researchers and clinicians have tirelessly strived to conquer this challenging disease, bringing hope and a better future to those affected by testicular cancer.

Date :
  1. Date Completed 1992-03-30
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

1792613

DOI: Digital Object Identifier

1792613

SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.